Selected Papers

Hutchinson M and Raff U
Sub-second MRI Data Acquisition Using Multiple Detectors.
Proceedings, Society for Magnetic Resonance in Medicine, 6th Annual Meeting August 17th 1987, New York.
Volume 1987, Issue Supplement S1, p. 459.

Hutchinson M and Raff U.
Fast MRI data acquisition using multiple detectors
Mag. Res. Med. 1988;6:87-91

Ansari AA, Mayne A, Freed CR, Breeze RE, Schneck SA, O’Brien CF, Kriek EH, Zhang YB, Mazziotta JC, Hutchinson M et al.
Lack of a detectable humoral/ cellular allogenic response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson’s disease.
Transplant Proceedings 1995;27(1):1401-5

Hutchinson M, Nenov V, and Mazziotta JC.
Neurosurgical applications of Positron Emission Tomography. Neurological Surgery, Fourth Edition,
ed by Youmans, J, pp172-184, Saunders, Philadelphia (1996)

Hutchinson M and Fazzini E.
Cholinesterase inhibition in Parkinson’s disease
J. Neurol. Neurosurg. and Psychiatry 1996;61:324-325

Hutchinson M, Rusinek H, Nenov VI, Feinberg DA and Johnson G
Segmentation analysis in functional MRI: overall sensitivity and gray matter specificity of FLASH and RARE.
J. Mag. Reson. Imaging 1997;7:361-364

Schlosser R, Hutchinson M, Joseffer S, Rusinek H, Saarimaki A, Dewey SL, Brodie JD.
Functional magnetic resonance imaging of human brain activity in a verbal fluency task.
J. Neurol. Neurosurg. Psychiatry 1998;64:492-498

Mazziotta JC, Hutchinson M, Fife TD and Woods R.
Advanced neuroimaging methods in the study of movement disorders.
Adv. Neurol. 1998;78:153-60

Hutchinson M and Raff U.
Parkinson’s disease: a novel MRI method for determining structural changes in the substantia nigra.
J. Neurol. Neurosurg. Psychiatry 1999;67:815-818

Hutchinson M.
“Diagnostic Evaluation: Functional Imaging”, in Vascular Malformations of the Central Nervous System,
eds. Jafar JJ, Awad IA, Rosenwasser RH, Lipincott, Williams & Wilkins, pp 209-216 Philadelphia, 1999

Hutchinson M, Schiffer W, Joseffer S, Liu A, Schlosser R, Goldberg E, Brodie JD.
Task specific deactivations in functional magnetic resonance imaging (fMRI). Mag. Res. Imaging 1999;17:1427-1436

Hutchinson M and Raff U.
Structural changes of the substantia nigra in Parkinson’s disease, as revealed by MR imaging.
Am. J. Neuroradiology 2000;21:697-701

Raff U, Rojas GM, Hutchinson M and Simon JH.
Quantitation of T2 lesion load in multiple sclerosis: a novel semi-automated MR segmentation technique.
Acad Radiol. 2000;7:237-249

Hutchinson M, Nakamura T, Moeller JD, Antonini A, Belakhlef A, Dhawan V, and Eidelberg D.
The metabolic topography of essential blepharospasm: a focal dystonia with general implications.
Neurology 2000;55:673-677

Aarsland D, Hutchinson M and Larsen JP.
Cognitive, psychiatric and motor responses to galantamine in Parkinson’s Disease with dementia.
Int. J. Geriatric Psych. 2003;18:937-941

Raff U, Rojas GM, Huete I and Hutchinson M.
Computer assessment of neurodegeneration in Parkinson’s Disease using data fusion techniques with MR images.
Acad. Radiol. 2003;10:1036-1044

Hutchinson M, Raff U and Lebedev S.
MRI correlates of pathology in parkinsonism: Segmented Inversion Recovery Ratio Imaging (SIRRIM).
NeuroImage. 2003;20:1899-1902

Hutchinson M and Lebedev S.
On the use of clusters to determine environmental influence on disease.
Arch. Neurol. 2005;62:331

Hutchinson M, Spanaki C, Lebedev S, Plaitakis A.
Genetic Basis of Common Diseases: General Theory of Mendelian Recessive Genetics.
Medical Hypotheses. 2005;65:282-286

Raff U, Hutchinson M, Rojas GM, Huete I.
Inversion recovery MRI in idiopathic Parkinson’s Disease is a sensitive tool to assess neurodegeneration in the substantia nigra. Academic Radiology. 2006;13(6):721-7

Penn R, Dalvi A, Slevin J, Young B, Gash D, Gerhardt G, Hutchinson M.
GDNF in the treatment of Parkinson’s Disease: response to editorial.
Lancet Neurology. 2006;5:202-203

Hutchinson M, Gurney S, Newson R
GDNF in Parkinson Disease: an object lesson in the tyranny of Type II.
J. Neuroscience Methods. 2007;163:190-192

Hutchinson M and Swanson PD
Chaos theory and the treatment of refractory status epilepticus: who benefits from prolonged anesthesia, and is there a better way?
Medical Hypotheses 2007;68:439-441

Rojas GM, Raff U, Quintana JC, Huete I, Hutchinson M
Image fusion in neuroradiology: three clinical examples including MRI of Parkinson’s Disease.
Computerized Medical Imaging and Graphics. 2007;31:17-21

Hutchinson M and Raff U
On false negatives in MRI studies of Parkinson’s Disease.
Movement Disorders 2007;22(10):383-385

Hutchinson M and Raff U
Detection of Parkinson’s Disease by MRI: Spin-Lattice Distribution Imaging.
Movement Disorders 2008;23(14):1991-1997

Hutchinson M
Neuroimaging of movement disorders.
Neurology Continuum 2008;14(4):164-174

Hutchinson M
On the toxicity of GDNF.
Toxicologic Pathology 2008;36:522

Hutchinson M
At last, a gene therapy for Parkinson’s Disease?
Lancet Neurol. 2011;10(4):290-291

Hutchinson M
Gene therapy for Parkinson Disease: where do we stand?
Journal Watch Neurology. 2011;13(7):51-52

Hutchinson M and Raff U
Spin-Lattice Distribution MRI maps nigral pathology in Progressive Supranuclear Palsy (PSP) during life: a pilot study.
PLOS ONE 2013, in press

Michael Hutchinson, MD

Neurologist located in New York, NY

Michael Hutchinson MD, PhD is a neurologist at New York Core Neuroscience serving patients in New York, New York. A graduate of the highly competitive PhD-to-MD program at the University of Miami, Dr. Hutchinson received his medical degree in 1988. During his residency training at the University of Washington, he developed a method of treating status epilepticus (the most lethal form of epilepsy) that is now the standard of care in the US. In addition to extensive training in multiple sclerosis, Dr. Hutchinson completed a two-year fellowship in neuroimaging at UCLA. He is currently Senior Faculty  at the Icahn School of Medicine at Mount Sinai, New York.

Dr. Hutchinson is board certified in both neurology and neuroimaging and is President of the American Society of Neuroimaging. He holds a PhD in molecular physics in addition to his medical degree. A medical pioneer, Dr. Hutchinson proposed a novel treatment for status epilepticus in 1990, now the standard of care. He was the first to use cholinesterase inhibitors for the dementia of Parkinson’s disease (1995) and developed a novel approach to treating acute relapses in multiple sclerosis (2002). He is the inventor of the parallel MRI (1987), which is now the world standard for magnetic resonance imaging.

Read more
New York Core Neuroscience

Michael Hutchinson MD, PhD is a neurologist at New York Core Neuroscience serving patients in New York, New York. A graduate of the highly competitive PhD-to-MD program at the University of Miami, Dr. Hutchinson received his medical degree in 1988. During his residency training at the University of Washington, he developed a method of treating status epilepticus (the most lethal form of epilepsy) that is now the standard of care in the US. In addition to extensive training in multiple sclerosis, Dr. Hutchinson completed a two-year fellowship in neuroimaging at UCLA. He is currently Senior Faculty  at the Icahn School of Medicine at Mount Sinai, New York.

Dr. Hutchinson is board certified in both neurology and neuroimaging and is President of the American Society of Neuroimaging. He holds a PhD in molecular physics in addition to his medical degree. A medical pioneer, Dr. Hutchinson proposed a novel treatment for status epilepticus in 1990, now the standard of care. He was the first to use cholinesterase inhibitors for the dementia of Parkinson’s disease (1995) and developed a novel approach to treating acute relapses in multiple sclerosis (2002). He is the inventor of the parallel MRI (1987), which is now the world standard for magnetic resonance imaging.


Read less
Services

Services

Affiliations

Accepted Insurance Providers

Our medical practice works closely with numerous insurance carriers to ensure that our patients get the care that they need and deserve. If you have any questions or do not see your insurance carrier listed, please contact our office directly. We now accept Oscar Commercial Insurance, and effective as of October 1st, Dr. Hutchinson is in-network with HIP Medicare Advantage and HIP commercial plans.

  Regence Blue Cross Blue Shield
1199SEIU
AARP
Aetna
Anthem Blue Cross
Anthem Blue Cross Blue Shield
Arkansas Blue Cross Blue Shield
Assurant Health
Blue Cross Blue Shield
Blue Cross Blue Shield of Florida (Florida Blue)
Blue Cross Blue Shield of Illinois
Blue Cross Blue Shield of Kansas
Blue Cross Blue Shield of Massachusetts
Blue Cross Blue Shield of Texas
Blue Cross of Idaho
Blue Cross of Northeastern Pennsylvania
Testimonials

Words from our patients

  • Yelp

    "Finding Dr. Hutchinson has saved my life from migraines that I have suffered from all my life. I love him! I highly recommend him to anyone who needs a neurologist."

    Lisa M.
  • Yelp

    "Dr. Hutchinson is a great physician. He takes time with his patients and really listens to his patients - which is a rarity today in health care!"

    Christine S.
Ask us

Feel free to email us regarding any scheduling or general questions!

Follow Us
Hours

Michael Hutchinson, MD
345 East 37th Street
Suite 320
New York, NY 10016